

## Special Issue

# Vaccines and Antibody-Based Therapeutics Against Infectious Disease

### Message from the Guest Editor

Infectious diseases remain a global challenge due to their continual resurgence and persistence, impacting humans and agriculture. It is important to prevent these diseases and epidemics. Although there have been recent advances in preventive therapeutics, there is still a need to develop vaccines and antibody-based therapeutic disease interventions. New approaches are needed, whether prophylactic or therapeutic, to advance the field and achieve better outcomes. This Special Issue aims to update advances in vaccine and antibody-based therapies. The collection will address current research and the development of new technologies and welcomes review and original research articles focusing on new horizons of immunity and therapy against infectious diseases that emphasize preclinical and clinical vaccines, antibody-based prophylaxis, and treatment regimens.

---

### Guest Editor

Dr. Suman Kundu

Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN, USA

---

### Deadline for manuscript submissions

31 December 2025



## Vaccines

---

an Open Access Journal  
by MDPI

---

**Impact Factor 3.4**  
**CiteScore 9.9**  
**Indexed in PubMed**



[mdpi.com/si/210857](https://mdpi.com/si/210857)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).